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Abstract: In recent years tryptophan metabolism and its rate limiting enzyme indoleamine 2,3-dioxygenase (IDO) have attracted 
increasing attention for their potential to modulate immune responses including the regulation of transplantation tolerance. The focus 
of this review is to discuss some features of IDO activity which particularly relate to hematopoietic stem cell transplantation (HSCT). 
HSCT invariably involves the establishment of some degree of a donor-derived immune system in the recipient. Thus, the outstanding 
feature of tolerance in HSCT is that in this type of transplantation it is not rejection, which causes the most severe problems to HSCT 
recipients, but the reverse, graft-versus-host (GvH) directed immune responses. We will discuss the peculiar role of IDO activity and 
accelerated tryptophan metabolism at the interface between immune activation and immune suppression and delineate from theoreti-
cal and experimental evidence the potential significance of IDO in mediating tolerance in HSCT. Finally, we will examine therapeutic 
options for exploitation of IDO activity in the generation of allo-antigen-specific tolerance, i.e. avoiding allo-reactivity while maintain-
ing immunocompetence, in HSCT.
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Introduction
principles of hematopoietic 
stem cell transplantation
Hematopoietic  stem  cell  transplantation  (HSCT) 
represents  a  potentially  curative  and  increasingly 
applied  approach  for  several  treatment  objectives. 
These,  for  example,  include  the  eradication  of 
malignant clones in case of hematologic malignancies 
but also the introduction of metabolic competence in 
some  inherited  metabolic  diseases  (e.g.  Pfaundler-
Hurler disease), or the replacement of hematopoietic 
cells in hematopoietic stem cell disorders (e.g. aplas-
tic anemia) and congenital immunodeficiencies (e.g. 
severe combined immunodeficiency). The conceptual 
basis of HSCT is to introduce a donor-derived hema-
topoiesis into the recipient with the aim to either com-
pletely replace the diseased hematopoietic system by 
an intact one or to substitute for a defect within the 
hematopoietic system. Importantly, since the immune 
system as a whole is an integral part of the hemato-
poietic system, HSCT invariably implies establishing 
a donor-type immune system. However, the immune 
system as such is not a transplantable organ but has 
to either expand from immune cells contained within 
the  graft  or  be  regenerated  from  the  transplanted 
hematopoietic  stem  cells.  In  general,  HSCT  will 
result  in  variable  degrees  of  coexisting  recipient-
type  and  donor-type  hematopoietic  and  immune 
cells.  In  transplantation  immunology  ‘chimerism’ 
means the presence of donor-derived hematopoietic 
cells within a recipient. These donor-derived immune 
cells, in principle, are ‘foreign’ to the host organism. 
Chimerism can either be ‘complete’ (defined by the 
presence of 99% donor-type hematopoietic cells) or 
‘mixed’ (any percentage of donor type hematopoietic 
cells ranging from 1% to 99%). Refined chime-
rism  studies  have  demonstrated  that  the  degree  of 
donor chimerism may be different in distinct hema-
topoietic or immune cell populations.1,2 Because any 
degree of chimerism implies the grafting of donor-
derived immune cells in an allogeneic host organism, 
it is obvious that after HSCT the reconstitution of 
an intact immune system is a challenging process. 
While HSCT has in recent years developed into a 
life-saving treatment option for most of the above 
mentioned disease states, its final treatment success is 
still hampered by the profound effects on the immune 
system  of  the  transplant  recipient,  which,  though 
transient, may result in unpredictable complications.
Transiently disturbed immunity  
in the post-HScT period (Fig. 1)
The  mammalian  immune  system  has  an  inherited 
prevalence  to  distinguish  ‘self’  from  ‘non-self’. 
The peculiarity of HSCT, in contrast to solid organ 
transplantation, is that the immunologic recognition 
of  ‘non-self’  (allo-recognition)  can  occur  in  both 
directions, i.e. as a host versus-graft (HvG) reaction 
(rejection) but also as a graft-versus-host reaction (see 
below). An essential principle for successful HSCT 
therefore is to carefully select the donor for match-
ing the recipient within the polymorphic major histo-
compatibility antigen (MHC) alleles. Human HSCT 
is mostly done in MHC identical siblings or MHC 
matched  unrelated  donors.  Despite  careful  MHC 
matching, the recipient immune system has first to 
be effectively suppressed to allow for engraftment 
and  prevent  the  host-versus-graft  (HvG)  reaction. 
This  is  performed  by  the  “conditioning  regimen” 
(Fig. 1) which regularly comprises high-dose chemo-
therapy with or without total body irradiation. Most 
conditioning  regimen  cause  long-term  or  irrevers-
ible  suppression  of  the  recipient  immune  system. 
Even in an uncomplicated post-transplant course the 
reconstitution of a more or less functionally intact 
immune system is a long-lasting process.3,4 While the 
immune cell populations forming the innate part of 
the immune system, like natural killer cells or mono-
cytes/macrophages, usually are rapidly reconstituted 
(within weeks), the adaptive part of the immune sys-
tem requires months and, in rare cases, even years 
to be fully recovered. The cellular compartment with 
the slowest reconstitution kinetics is the T-cell sys-
tem. The recovery of T cells is a complex process as 
T cells are composed of multiple subsets with dif-
ferent functions and with different degrees of thy-
mic activity required for their reconstitution.5–7 T cell 
reconstitution may simply occur by the expansion of 
residual T cells contained in the graft.8 The expan-
sion of such T cells is independent of residual thymic 
activity. However, it has been shown that these T-cells 
have a limited functional capacity, because they are 
determined in their antigen specificity and thus have 
a  limited  T-cell  receptor  repertoire.8,9  The  common Indoleamine 2,3-Dioxygenase in HScT
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understanding is that the reconstitution of the newly 
produced naïve T-cells ensures the regeneration of a 
well  functioning T-cell  system  after  HSCT.7,10 The 
generation of new T-cells, in particular the T helper 
(CD4+) subsets, has been shown to be strictly depen-
dent on residual thymic activity.5,6 If the thymus has 
been surgically removed or if thymic activity is low, 
as in the elderly, the reconstitution of a functional 
CD4+ T-cell population usually is unsatisfactory. It is 
common knowledge that T-cells are the major execu-
tors of detrimental allo-responses.3
Nowadays,  allo-responses  in  the  HvG  direction 
(rejection) can usually be successfully controlled in 
HSCT.  However,  the  newly  developed  donor-type 
T-cells  reappearing  during  the  process  of  hemato-
poietic  reconstitution  are  inclined  to  mount  allo-
responses  against  the  recipient,  i.e.  to  initiate  an 
immune response directed against the organism, in 
which they begin to expand (graft-versus-host reac-
tion,  GvH).  The  GvH  reaction  can  give  rise  to  a 
clinically  severe  and  difficult-to-treat  immune  dis-
order,  graft-versus-host  disease  (GvHD).  GvHD 
continues to represent a significant factor in limiting 
the survival and quality of life in patients receiving 
HSCT.  GvHD  can  affect  every  organ  system  but 
mainly causes skin, liver and/or gut disease and may 
exacerbate into a life-threatening condition. GvHD 
can occur in an acute or chronic form with 100 days 
after HSCT being the widely accepted cut-off time 
point to discriminate acute from chonic GvHD.11 The 
distinction between acute and chronic GvHD is clini-
cally relevant as both, the clinical appearance as well 
as the pathogenesis are seemingly different and may 
require different treatment.12–14 Chronic GvHD may 
resemble a chronic autoimmune disease rather than 
the acute form.
The prevailing susceptibility of HSCT recipients to 
develop GvHD requires long term prophylactic phar-
macological immunosuppression, i.e. to be continued 
even after engraftment, which usually occurs by day 30 
after HSCT (Fig. 1). GvHD emerging despite phar-
macologic  prophylaxis  causes  immunosuppression 
per se, but its treatment uniformly requires intensi-
fication  of  the  immunosuppressive  therapy.  Taken 
together (i) the necessity to ablate the recipient type 
immune system prior to HSCT, (ii) the slow regen-
eration  kinetics  of  the  transplanted  immune  cells, 
particularly the T-cells, and (iii) the requirement of 
pharmacological immunosuppression after HSCT to 
prevent or to treat GvHD, leaves HSCT recipients 
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Figure  1.  Immunodeficiency  after  HSCT.  The  figure  comprises  some  important  factors  that  invariably  contribute  to  the  immune  deficiency 
after HScT. The numbers of the scale indicate days after transplant. Immediately after transplantation the number of immune cells is diminishing, and the 
appearance of donor-derived immunocompetent cells requires some time. Therefore, the risk for GvHD increases as donor-derived immune cells reappear 
in the recipient.Jürgens et al
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in an immunosuppressed state (Fig. 1). Thus, HSCT 
recipients are generally highly vulnerable to infections 
by  pathogens  which  otherwise  are  either  harmless 
or held under control by an intact immune system. 
Among these ‘opportunistic’ infections viral (e.g. by 
cytomegalovirus or adenovirus) or fungal infections 
(candida,  aspergillus  species)15  are  most  prevalent 
and can be life-threatening. Thus, the HSCT related 
immune  insufficiency  is  associated  with  a  risk  of 
transplant-related morbidity and mortality (TRM). To 
minimize the risk for TRM has turned into a major 
goal in the transplantation community.
Nevertheless,  despite  these  immunological 
hazards, HSCT recipients, different from recipients 
of  solid  organ  transplantation,  eventually  regain 
functional immune competence and frequently can 
be weaned from pharmacologic immunosuppression 
without  re-developing  allo-responses  neither  in  the 
HvG nor in the GvH direction. This is compatible 
with a state of true immunological tolerance. Thus, 
a main task to be accomplished in making HSCT a 
safe and broadly applicable treatment approach is to 
bridge the period  of  profound  immune-dysfunction 
which occurs after HSCT as long as tolerance is not 
fully achieved.
Some mechanisms of allo-recognition
Establishing  a  donor-derived  immune  system  in  a 
host, i.e. in a ‘non-self’ organism, is a complex pro-
cess. A paradigm of mammalian immunity predicts 
that the recognition of non-self will lead to stimula-
tion of an immune response irrespective of whether 
or not a microbial antigen is involved. It is a unique 
feature of allo-reactivity in the mammalian immune 
system that the precursor frequency of T-cells rec-
ognizing  allo-antigens  is  two  to  three  logs  higher 
than the precursor frequency for cognate antigens.16,17 
Thus, the initiation of allo-responses is predominant 
after HSCT.
The  recognition  of  allo-antigens  primarily 
involves  disparate  major  histocompatibility  (MHC) 
molecules (reviewed in18). MHC class I molecules are 
expressed on cells throughout the body, while MHC 
class II molecules are restricted to antigen present-
ing  cells  (APC).  Both  classes  of  MHC  molecules 
can serve as targets for allo-recognition. It has been 
proposed that the T-cell receptor (TCR) complex has 
an inherent affinity for the MHC surface and thus, 
allo-responses can occur towards polymorphisms of 
the MHC—including the secondary and even tertiary 
structure of the MHC complexes—as well as to the 
peptide presented in the context of MHC complexes.16 
In case of an MHC matched HSCT only the MHC-
bound peptides can serve as target allo-antigens. For 
example, non-microbial peptides derived from poly-
morphic proteins differently encoded in the host and 
the donor, collectively called minor histocompatibil-
ity antigens (miHags),19 can elicit strong allo-immune 
responses,20 even if these differences are minimal, e.g. 
caused by single nucleotide polymorphisms (SNP).21 
Of note, different from conventional antigen presenta-
tion the presentation of allo-antigens is a limitless pro-
cess, in other words the antigen cannot be eliminated 
and cannot be made innocuous.18 The only way for 
the donor immune system to attenuate the allo-anti-
gen targeted immune response is to become tolerant. 
To understand the mechanisms of the development of 
transplantation tolerance has become a center of atten-
tion in solid organ and hematopoietic transplantation.
In the context of HSCT the recognition of allo-
antigens can occur in two ways. One is that donor 
T-cells recognize recipient-derived APCs as foreign, 
“direct  antigen  recognition”.  Alternatively,  donor-
derived APCs can present recipient-derived antigens 
to donor T-cells; this process is called “indirect anti-
gen recognition”. According to a recently presented 
concept18  the  initiation  phase  of  GvHD  involves 
direct  antigen  recognition  of  miHags,  while  the 
evolution of overt GvHD may preferentially involve 
indirect allo-antigen recognition. The individual risk 
of HSCT recipients to develop GvHD in humans has 
been described to involve the universe of the immune 
reactions  starting  from  genetic  polymorphisms  of 
cytokine genes22 to affecting multiple immune cell 
subsets to finally resulting in the multifaceted clini-
cal forms of GvHD. On the cellular level, the devel-
opment  of  allo-antigen  directed  tolerance  appears 
to  require  two  complementary  steps,  the  elimina-
tion and the regulation of allo-reactive cells.23 What 
becomes clear from the current knowledge of GvHD 
is that the processes involved in its development are 
multifaceted and that targeting a single step may not 
be a promising approach. However, as stated above, 
HSCT is a procedure which in most cases results in 
clinical tolerance induction, i.e. HSCT recipients can 
be weaned from pharmacological immunosuppression Indoleamine 2,3-Dioxygenase in HScT
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while maintaining the donor-type immune cells and 
regaining a state of immunocompetence.
Multiple scientific efforts have been undertaken to 
understand the basic principles of tolerance induction 
in transplantation in general. In HSCT, in particular, 
the  ultimate  goal  to  improve  the  final  outcome  in 
HSCT is to efficiently strengthen the immunocom-
petence of the recipient in the defense of pathogens 
while avoiding the risk of promoting GvHD. In other 
words, donor-derived T-cells must be made tolerant 
to the host but retain their immuncompetence against 
microbial pathogens (allo-antigen-specific tolerance) 
(Fig. 2).
Tolerogenesis by Tryptophan 
Metabolism
Among  the  numerous  approaches  to  tolerance 
induction,  the  role  of  tryptophan  metabolism  has 
attracted  increasing  interest  in  the  past  ten  years. 
This interest is based on research which unravelled 
accelerated tryptophan catabolism as a critical factor 
in  modulation  of  immune  responses.  The  basic 
details of the biochemistry and biology of trypto-
phan and tryptophan metabolism have recently been 
excellently reviewed by Chen Y and Guillemin GJ 
in this journal.24 For the purpose of understanding 
the role of tryptophan and its metabolism in human 
HSCT it is worthwhile to emphasize the following: 
1) Tryptophan is an essential aminoacid, i.e. it can-
not be newly synthesized but has to be taken up 
by diet, and thus is of limited availability for the 
organism. Human T-cells, once being stimulated 
to  proliferate,  essentially  depend  on  the  avail-
ability of tryptophan to synthesize new proteins. 
2)  Tryptophan  breakdown  occurs  mainly  along 
the kynurenine pathway. Two enzymes act as rate-
limiting compounds, tryptophan 2,3-dioxygenase 
(TDO),  whose  activity  is  restricted  to  the  liver, 
and  indoleamine  2,3-dioxygenase  (IDO),  which 
is  active  throughout  the  body.  Both,  TDO  and 
IDO initiate tryptophan breakdown by catabolis-
ing the oxidative cleavage of the indole-ring into 
N-formylkynurenine  and  kynurenine. Thus,  IDO 
serves as the main tryptophan-degrading enzyme 
in the human body. 3) An accelerated activity of 
IDO results in tryptophan depletion and accumu-
lation  of  biologically  active  tryptophan  down-
stream  metabolites,  e.g.  3-hydroxy-kynurenine, 
3-hydroxy-anthranilic  acid  and  quinolinic  acid. 
4)  A  controversy  still  exists  which  of  the  two 
metabolic effects of IDO activity are predominant in 
mediating immunoregulation, tryptophan depletion 
allo-antigen-specific tolerance
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Figure 2. Allo-antigen-specific tolerance. The post-transplant immune system, which will contain some degree of donor-chimerism (see text), is required 
to specifically be devoid of allo-reactivity in both directions, HvG and GvH, but to protect from microbial infections and provide immune reactivity against 
neoplastic cells (graft-versus-leukemia, GvL, and graft-versus-tumor, GvT).Jürgens et al
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or  the  accumulation  of  tryptophan  metabolites. 
Yet,  in  a  comprehensive  view,  it  seems  that, 
especially in vivo, these effects cannot be clearly 
separated; rather both of them eventually will affect 
immune responses in a complementary fashion (see 
below).
The current concept of the immunologic conse-
quences  of  IDO  activity  holds  that  IDO  regulates 
immune responses by an alteration of the composition 
of the soluble intercellular microenvironment in which 
T-cells encounter antigen (Fig. 3). T-cells themselves 
have not been observed to express IDO. Instead, IDO 
expression and activity, hereafter termed IDO compe-
tence, has thus far been demonstrated in multiple cell 
types, among which are tumor cells,25 fibroblasts26 
bronchial  epithelial  cells27  and  eosinophils,28  and, 
most prominently, in the classical APC populations.29 
In  the  human  body  the  essential APC  populations 
comprise monocytes, macrophages, and the dendritic 
cells (DCs). These cell populations are equipped with 
an  intracellular  machinery  to  process  antigen  and 
present antigenic peptides in the context of an MHC 
molecule to T-cells by getting in close contact with the 
responding T-cells within the immunologic synapse. 
In  fact, T-cells  for  mounting  an  immune  response 
are dependent on recognizing processed antigen on 
the surface of APC in the context of self MHC com-
plexes. T-cells, as they comprise the major fraction of 
the effector arm of the immune system, when being 
deprived from the access to tryptophan and exposed 
to  tryptophan  metabolites  are  disabled  to  mount  a 
full effector immune response. The T-cell inhibitory 
mechanisms include cell-cycle arrest in the mid G1 
phase30 and initiation of a stress response indicated by 
up-regulation of the general control non-depressible-2 
(GCN2) kinase.31 Tryptophan metabolites have been 
shown  to  act  as  pro-apoptotic  agents  particularly 
affecting activated murine32,33 and human34 T-cells. In 
addition, IDO activity supports the differentiation of 
T-cell regulatory activity (Treg) activity, i.e. IDO has 
been shown to endow T-cells with the ability to sup-
press other T-cell responses.35–38
The molecular pathways by which IDO induces 
tolerogenic capability of DCs include the interaction 
of the programmed death receptor ligand 1 (PD-L1) 
and PD-2L with its receptor PD-1, which is expressed 
on T-cells.39 In addition, the IDO induction in DCs is 
accompanied by the expression of the high-affinity IL-2 
APC
IDO
T cells
pro-apoptotic
Fas dependent, caspases
kynurenine
accumulation
tryptophan
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Figure 3. Hypothetical model of IDO activity in the regulation of immune responses. It is presumed that the main effects of IDO-mediated tryptophan 
breakdown, tryptophan depletion and kynurenine accumulation, act in concert to modulate T cell responses. Note, that according to the model T cells that 
are not responsive to the antigen presented are considered to remain largely unaffected by the effect of IDO.Indoleamine 2,3-Dioxygenase in HScT
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receptor, CD25. CD25 can be released from the DC 
surface and this soluble CD25 molecule (sCD25) 
can  act  as  a  scavenger  for  IL-2  secreted  by  acti-
vated T-cells and thus limit IL-2 dependent T-cell 
proliferation.40 Together,  IDO  activity  in APCs  is 
viewed as a critical factor to down-regulate T-cell 
responsiveness.
IDO as a Feedback Mechanism 
of Immune Activation
One significant aspect to consider for the compre-
hensive understanding of the biological relevance of 
IDO activity is its link to immune activation. Indeed, 
in human APCs IDO competence is usually not con-
stitutively present but is induced upon APC activa-
tion. Multiple factors have been described to be able 
to  activate  APCs  and  concomitantly  induce  IDO. 
These  include  TLR  agonists,  e.g.  CpG  interacting 
with TLR9,41 or LPS interacting with TLR4.36 Fur-
thermore,  strong  inducers  of  IDO  competence  are 
type  I  and,  most  prominently,  type  II  interferons 
(IFN-g) (reviewed in42). All these compounds have 
originally been associated with immune activation. 
In the research addressing the link of immune stimu-
lation and the induction of immune inhibition medi-
ated  by  IDO  activity  two  important  observations 
have been made. One is the phenomenon of ‘reverse 
signaling’.43 This term describes a process in which 
molecules, which are involved in immune activation, 
may transmit an inhibitory signal if they act as recep-
tors of inhibitory signals. Such a mechanism has been 
proposed to be operative in murine DCs through the 
interaction of CTLA-4 with CD80 or CD86. CD80 
and CD86, being expressed on DCs, have been rec-
ognized potent “costimulatory” signals, indispensible 
for stimulation of a full T-cell response, as they inter-
act with CD28 expressed on T-cells. In the reverse 
setting CTLA-4 which is expressed on T-cells upon 
activation or present on regulatory T-cells can bind 
to  CD80/CD86  and  transmit  an  inhibitory  signal 
which finally results in IDO induction and a tolero-
genic activity of DCs.44 Another example of reverse 
signalling is the interaction of GITR (on T-cells) with 
its ligand GITR-L on plasmacytoid DCs,45 in which 
the inhibitory function of DCs also occurs in an IDO-
dependent fashion.
The  second  important  observation  is  a  timely 
distinct kinetics of the activity of pro-inflammatory 
cytokines and IDO in IFN-g activated DCs.38 In these 
in  vitro  studies  it  was  shown  that  in  human  DCs 
activated with LPS and IFN-g, the presence of IFN-g 
induced pro-inflammatory cytokine release and IDO 
activity in parallel, however with a timely distinct pat-
tern. The DCs’ capacity to release pro-inflammatory 
cytokines quickly emerged (4 hours) but ceased after 
48  hours  of  stimulation.  In  contrast,  IDO  activity 
developed slowly, but the DCs’ capacity to effectively 
metabolize tryptophan and accumulate kynurenine was 
maintained beyond the 48 hour stimulation period and 
even after the stimulants were removed. Thus, when 
DCs were used as stimulators of T-cells shortly after 
activation with IFN-g, i.e. when cytokine production 
prevailed, the resulting T-cell response was polarized 
towards a Th-1 phenotype;46 on the contrary, when 
allogeneic T-cells were encountered by DCs at a time 
point after which cytokine production was terminated 
but IDO activity continued, the T-cell response was 
either quantitatively down-regulated or a regulatory 
type of T-cell response was induced.38 In their com-
posite, these findings support a physiological role for 
IDO to act as a negative feedback response for limita-
tion of an ongoing immune response.47 The immune 
dampening effect of IDO may be of value for the host 
to control for the magnitude of an immune response 
and prevent exaggerated or misguided immune reac-
tions  which  potentially  result  in  organ  damage  or 
autoimmunity. Alternatively, overt IDO activity may 
become  counterproductive  and  contribute  to  caus-
ing immunodeficiency. IDO-mediated immune sup-
pression, for example, is predominant in situations 
of  chronic  immune  activation,  such  as  cancer48  or 
HIV infection.49 In fact, in the clinic the position of 
IDO at the crossing point of immune activation and 
immune dampening may make the interpretation of 
the presence of IDO activity difficult. An enhanced 
IDO activity in humans—indicated by low trypto-
phan and elevated kynurenines in the serum—may 
indicate overt immune activation, i.e. rejection,50 or 
down-regulation of immune responses as shown in 
HIV infection51 or beneficial immune regulation in 
the direction of tolerance.52
A particular role for IFN-gamma
For appreciating the role of IDO being involved in 
maintaining  the  balance  between  immune  activa-
tion and immunosuppression it seems worthwhile to Jürgens et al
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re-consider the ambivalent role of IFN-g. Within the 
immune system IFN-g has been recognized as one 
of  the  most  potent  inducers  of  IDO,53  particularly 
inducing  a  prolonged  activity  in  (DCs).38  On  the 
other  hand,  IFN-g  has  long  been  appreciated  as  a 
prototypic pro-inflammatory cytokine (reviewed in54). 
Its pro-inflammatory activity was linked to its ability 
1) to enhance the antigen-presenting capacity of APCs 
by increasing the level of expression of class II mole-
cules, 2) to stimulate the microbicidal activity of mac-
rophages, 3) to drive Th-1 polarization of T cells and 
4) to promote B-cell maturation and the IgG 2a pro-
duction, thus, being essential in stimulating immune 
responses. Contrasting this pro-inflammatory effect, 
IFN-g  has  definitively  been  shown  to  be  essential 
in dampening immune responses in autoimmunity55 
and transplantation.56 The pathways underlying the 
immunoregulatory  effect  of  IFN-g  clearly  overlap 
with  the  immune  dampening  effects  of  IDO.  Like 
IDO  activity,  IFN-g  has  been  shown  to  promote 
apoptosis  of  T-cells.57–59  The  pro-apoptotic  activity 
of IFN-g seemingly does not affect all T-cell subsets 
equally, i.e. it appears to preferentially affect acti-
vated T-cells and to spare regulatory T-cells. In fact, 
IFN-g signalling appeared to be essentially required 
for Treg activity.60,61 In the allogeneic setting Sawitzky 
et al demonstrated IFN-g release by the allo-antigen 
reactive Treg cell population to support their suppres-
sive  function.62  Several  studies  showed  that  IFN-g 
induces metabolic processes, which ultimately alter 
the intercellular microenvironment in which APCs 
and  potentially  responsive  T-cells  interact.  These 
metabolic alterations include, for example, the induc-
tion of hemoxygenase-1 (HO-1),63 or arginase-164 and 
IDO. The enzymatic activities of these enzymes are 
associated with down-regulation of immune response. 
Of note, these enzymes are closely cross-regulated 
and can interact with each other.65–67 Thus far, it seems 
that the close alliance of IDO and IFN-g is particu-
larly relevant in immunomodulation. IFN-g plays a 
critical role in the above mentioned model of ‘reverse 
signalling’ of CTLA-4-Ig to CD80/86 on DCs; The 
signal transmitted by CTLA-4 to CD80/CD86 results 
in the release of INF-g in a STAT-1 dependent fashion 
and this IFN-g secretion acts in an autocrine loop to 
finally cause IDO expression and activity.68 Likewise, 
as described above in detail, IFN-g is a critical factor 
in the induction of strong and sustained IDO activity in 
human monocyte-derived DCs.38 Furthermore, IFN-g 
has been shown to be a critical factor involved in the 
immunosuppressive state that accompanies chronic 
immune activation. In an elegant study Bronstein 
Sitton  et  al  reported  that  mice  undergoing  serial 
bacterial  challenges  developed  a  severe  immune 
dysfunction, which was related to a chronic release 
of IFN-g.69 In this model sustained immune activa-
tion was accompanied by down-regulation of the 
TCR-z chain expression, which is strictly associ-
ated with down-regulation of T cell responsiveness. 
The down-regulation of TCR-z chain is a promi-
nent effect of arginine depletion, but an accelerated 
tryptophan metabolism as induced by IDO has been 
shown to also exert this effect in a murine model.35
Altogether,  these  findings  conceptually  support 
that pro-inflammatory IFN-g induces its own feedback 
mechanism and the IDO pathway may play a critical 
role in this feedback process.47,70
In  the  setting  of  HSCT  IFN-g  has  originally 
been  suggested  to  be  involved  in  the  pathogen-
esis  of  GvHD.71–73  However,  more  recent  work 
provides  sound  evidence  that  IFN-g,  in  particular 
donor-derived IFN-g, is a critical cytokine to attenu-
ate  GvHD.74  IFN-g  has  been  reported  to  promote 
allo-reactivity towards recipient hematopoietic cells 
but to spare host epithelial cell damage75 and con-
tribute to the graft-versus-leukemia (GvL) effect. In 
turn, the absence of IFN-g promoted the develop-
ment  of  organ-destructive Th-17  cells.76  However, 
in another study the transplantation of IFN-g defi-
cient bone marrow was shown to reverse subclinical 
GvHD and to enhance graft-versus-tumor activity.77 
These findings support the crucial but dichotomous 
role of IFN-g.78
The post-HScT period—a state  
of chronic immune activation
The immunodeficient state after HSCT has originally 
been understood as to result primarily from the absence 
of  essential  components  of  the  immune  system 
caused by the delay of the recovery of immunocom-
petent  cells.  More  recent  evidence,  however,  sug-
gests that in addition to the quantitatively decreased 
number of immunocompetent cells the immunodefi-
cient state after HSCT is also due to the dysfunction 
of the residual and even the newly regenerated cells.5 
To this end, our previous studies79 of the immuno-Indoleamine 2,3-Dioxygenase in HScT
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suppressive  monocyte-mediated  effect  after  HSCT 
have shown that it may not simply be the presence 
of, but the sensitivity to IFN-g, which is responsi-
ble for down-regulating immune responsiveness in 
HSCT. Indeed, our studies suggested that after HSCT 
monocytes are in a state of chronic activation and 
display  an  increased  sensitivity  to  IFN-g  and  can 
turn into suppressor cells upon the exposure to even 
small amounts of IFN-g through the initiation of IDO 
activity.
The Role of IDO in Human HscT
The primary detection of IDO activity as a pivotal 
pathway to down-regulate immune responses inclu-
ded  some  models  of  allo-antigen  driven  immune 
responses (reviewed in29,80). In the pioneering study 
of Munn and Mellor, which paved the way for rec-
ognizing IDO and tryptophan metabolism as a key 
immunoregulatory  mediator,  they  demonstrated  an 
enhanced frequency of abortion upon the blockade of 
tryptophan metabolism, in a model of semi-allogeneic 
pregnancy.81 As described above, allogeneic immune 
reactions  represent  a  unique  form  of  mammalian 
immunity. Since IDO activity was shown to be able to 
down-regulate allo-antigen driven immune responses 
it appeared obvious to set out for studying a role for 
IDO specifically in transplantation tolerance, includ-
ing HSCT. As outlined above, the peculiar feature of 
HSCT is that it involves allogeneic reactions in both 
directions, HvG and GvH.
A role of IDO and its ability to modulate GvHD 
has recently been addressed in several experimen-
tal murine models. By using B57BL/6 IDO knock 
out  mice  as  recipients  of  wild  type  Balb/c  donors 
Jasperson et al. showed that the capability to express 
IDO  and  efficiently  metabolize  tryptophan  plays 
a critical role in protecting from GvHD lethality.82 
Interestingly, in this model, different from the gen-
eral  opinion,  that  IDO  induces  transplantation  tol-
erance through the induction of regulatory T-cells, 
the IDO effect was not dependent on donor regula-
tory T-cells. In a subsequent study the same authors 
showed that donor T-cell derived IFN-g was critical 
for  the  up-regulation  of  IDO  expression  by APCs 
and the protection from GvHD in the colon of recipi-
ents.83 This effect seemingly was related to the effect 
of tryptophan metabolites rather than of tryptophan 
starvation. In a similar model of experimental GvHD 
Reddy and co-workers showed that DCs exposed to 
histone deacetylase inhibitors (HDAC) expressed 
IDO and upon adoptive transfer acquired the capacity 
to ameliorate experimental GvHD.84
One  particularly  interesting  model  was  recently 
presented by Romani et al.85 In this model the authors 
found a significant association of IDO expression in 
plasmacytoid DCs (pDCs) and the protection from 
Aspergillus  infection  after  experimental  HSCT. 
pDCs possess a high affinity to IDO competence in 
mice,86,87 and humans.37,88 In their model of experi-
mental  HSCT  DCs  obtained  from  B57BL/6  mice 
which  had  been  stimulated  by  Flt3L  became  IDO 
competent. When these DCs were pulsed with Asper-
gillus fumigatus they contributed to the development 
of protection against fungal infection, as shown by 
prolonged survival time and reduced fungal growth 
in infected mice. In contrast, the adoptive transfer 
of DCs, which had been stimulated by granulocyte-
macrophage colony stimulating factor (GM-CSF) only 
and did not develop IDO competence, failed to confer 
protection against fungal infection. When T-cells were 
co-administered with the DCs, the GM-CSF activated 
DCs favored the development of GvHD while Flt3L 
activated DCs failed to do so. Thymosin α-1 (Tα1) is 
a naturally occurring peptide,89 which, by signaling 
through TLR 9, promotes DC activation of murine 
and human DCs.90 The exposure of DCs to Tα1 led to 
the induction of IDO activity in either DC population, 
irrespective  of  whether  the  DCs  were  additionally 
stimulated by GM-CSF or Flt3L. Upon IDO induc-
tion by Tα1 either DC population acquired protec-
tive capacity against Aspergillus fumigatus infection. 
Thus, it seems that in some specific situations, such 
as fungal infection, which is highly relevant in HSCT 
(see Introduction), IDO expression by pDC may exert 
a dual effect, protecting from GvHD and protecting 
from fungal infection. This, at first sight, seems to be 
a paradox because IDO activity is generally viewed 
as being associated with immunosuppression.91 But 
further in-depth studies of the same group showed 
that the effect of IDO in the circumstance of fungal 
infection was to prevent the organ-destructive activity 
of Th17 cells and shift the immune response towards 
a  Th1  polarized  response.  Thus,  fungal  infection 
seemingly represents an example, where the attenu-
ation of an immune response might finally be to the 
benefit of the host. In the setting of experimental Jürgens et al
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HSCT and Aspergillus infection IDO appears as a 
critical factor mediating such an immunomodifying 
effect. The effect of IDO activity was suggested to 
be related to the induction of IFN-g producing Th-1 
cells, and foxp3 expressing and IL-10 producing regu-
latory T-cells.85
The knowledge of IDO in human HSCT is limited. 
As described above, in our studies of the mechanisms 
of  T-cell  deficiency  after  HSCT  we  unexpectedly 
discovered that the inability of T-cells to adequately 
mount  a  proliferative  response  to  antigens  essen-
tially involved a suppressor activity of post-HSCT 
monocytes.  Further  investigations  indicated  that 
the post-HSCT monocytes were highly sensitive to 
react to even low doses of IFN-g by the activation 
of IDO and release of kynurenines.79 Another study 
directly tested an association of IDO and GvHD in 
clinical HSCT.92 These authors reported that the abil-
ity to express IDO in response to stimulation with 
IFN-g was inversely correlated to grade of GvHD 
after allogeneic HSCT.
An interesting role for IDO may come into play when 
considering mesenchymal stem cells (MSCs). These 
cells  represent  a  recently  identified  cell  population, 
which has attracted high interest in the transplantation 
field because of their uniquely powerful tolerogenic 
effect (reviewed in93). In brief, MSCs are rare bone mar-
row derived cells, which have a stem-cell-like behavior 
as indicated by their ability to develop into bone, carti-
lage and fat tissue. Besides their stem-cell like capacity 
MSCs have been recognized as to potently down-regu-
late T-cell responses. MSCs have been found to inter-
fere with multiple cell types, including DCs, and the 
interaction of DCs with natural killer cells, and T-cells. 
For example, MSCs have been shown to down-regulate 
NK function, i.e. NK cell proliferation and NK cyto-
toxicity,  by  down-regulating  NK  receptors  NKp30, 
NKp44 and NKG2D in an IDO and PGE2 dependent 
fashion.94 MSCs may have a direct effect on T-cells by 
arresting activated T-cells in the G0/G1 phase of cell 
cycling95 and to induce apoptosis in activated T-cells.96 
Furthermore, MSCs have been reported to attenuate 
CD8-mediated  cytotoxicity.97  MSCs  also  indirectly 
modulate T-cell  responses  by  affecting  DC  matura-
tion and their development into regulatory DCs.98 For 
example MSCs have been shown to interfere with the 
pro-inflammatory effect of myeloid DCs by inhibiting 
TNF-α production and to favor IL-10 production by 
pDCs, thus, triggering Treg cell differentiation.99 As 
well, MSCs may act via bystander cells as they induce 
monocytes to release immunosuppressive molecules 
such as IL-10.100 MSCs do not constitutively express 
IDO but turn into IDO competent cells by an expo-
sure  to  IFN-g101  and  IFN-g  exposed  MSCs  being 
induced to express IDO acquire the ability to suppress 
T-cell and NK cell proliferation.102 IDO, though, may 
not be the exclusive mediator of the MSCs’ immuno-
regulatory actitivity. Several other factors have been 
proposed  by  which  MSCs  exert  their  tolerogenic 
effect,  including  nitric  oxide,103  or  HO-1.104  It  may 
well be that these effectors act in concert with other 
immunomodulators such as cyclooxygenase 1 and 2 
and hepatocyte growth factor.105 It is intriguing to note 
that many of these factors are induced by IFN-g, thus, 
underlining the multifaceted functions of this cytokine. 
In the context of regulating allo-responses MSCs have 
been observed to affect allogeneic immune effector 
cells more than virus-specific responses.106 The out-
standing  tolerogenic  capacity  attributed  to  this  cell 
population has led to the introduction of MSCs in a 
number of clinical trials addressing the question of a 
beneficial effect in the control of GvHD in HSCT.107 
However, in the reverse, the potent immunoregulatory 
capacity of MSCs has also been associated with tumor 
metastasis108 and with leukemia relapse,109 thus point-
ing at the fine line of the beneficial and adverse effects 
of adoptive cell transfer therapies with potently immu-
noregulatory cell populations.
exploitation of IDO in HScT
The thus far promising role for IDO activity for the 
development of transplantation tolerance has stimu-
lated research for the therapeutic use of IDO activ-
ity  in  promoting  allo-antigen-specific  tolerance  in 
HSCT. Pre-clinical models confirmed that IDO trans-
genic DCs do have the potential to induce tolerance in 
HSCT. A study of Mulley et al. showed that IDO can 
act in concert with other immunoregulatory pathways, 
such as IL-10, CTLA-4-Ig or CD40-Ig in the preven-
tion of graft rejection in a xenogeneic transplantation 
model.110 In a second study Wee et al. showed that 
pig-DCs transgene for the full length of human IDO 
were able to delay xeno-graft rejection.111
When considering the exploitation of IDO in human 
HSCT in a clinical context, it has to be emphasized 
that the use of this immunoregulatory pathway should Indoleamine 2,3-Dioxygenase in HScT
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circumvent  strategies  that  would  finally  aggravate 
the immunosuppressed state of the transplant recipi-
ent (see above). Thus, for example, a transfer of IDO 
expressing  or  transgenic  DCs  is  predicted  to  have 
a  generalized  immunosuppressive  effect,  probably 
increasing the anyhow exceptionally enhanced sus-
ceptibility of the recipient to the same opportunistic 
infections and/or to a diminished anti-tumor or GvL 
effect as conventional immunosuppressants.
Rather it seems feasible to use IDO expressing 
DCs or MSCs in an ex-vivo setting for the generation 
of  allo-antigen-specific  tolerance  (Fig.  4).  The 
hypothesis of this approach is that in an MLR using 
the  recipient  type  IDO  competent  cells  (which 
express  solely  recipient  type  allo-antigens)  and 
allogeneic, donor-derived T-cells (which are naïve 
to the presented allo-antigen), the allogeneic T-cells 
would become tolerant through IDO activity in the 
stimulating cells in an allo-antigen-specific fashion. 
This means that the allo-responsive T-cells are being 
tolerized whereas the non-allo-reactive T-cells are 
left unaffected. Thus, these T-cells may eventually 
be suitable for being used in adoptive cell transfer 
strategies as they would provide a source of cells 
with a retained ability to protect against microbial 
antigens  while  not  carrying  the  risk  of  initiating 
GvHD.
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Figure 4. Exploitation of IDO activity to generate allo-antigen-specific tolerized T cells. After an ex vivo mixed leukocyte reaction of recipient IDO 
competent Apcs and donor T cells the recovered T cells are supposed to be unable to mount allo-responses in the GvH direction due to the effects of IDO 
but retain the immune competence against microbial pathogens. These T cells should therefore be suitable for being adoptively transferred to the recipient 
to provide transient immunocompetence but avoid GvHD induction.Jürgens et al
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